Skip to main content
SpringerLink
Log in

111In-Octreotide Infusions for the Treatment of Bronchopulmonary Neuroendocrine Neoplasms

  • Chapter
  • First Online:
Liver Intra-arterial PRRT with 111In-Octreotide

  • 225 Accesses

Abstract

Bronchopulmonary neuroendocrine neoplasms (BPNΝs) are slow-growing, low-grade malignant neoplasms, comprising 1–2% of all primary lung cancers. They are thought to arise from neuroendocrine (Kulchitsky’s cells) of bronchial epithelium. Histological features range from low-grade typical to more aggressive atypical neoplasms. Although PRRT for the gastropancreatic tumors (GEP NETs) consists the therapy of preference, that is not the case with BPNΝs. This chapter is dealing with the evaluation of the effectiveness of peptide receptor radionuclide therapy (PRRT) in patients with BPNN as well as liver-metastasized PRRT of bronchopulmonary origin and describes the Auger and internal conversion electron efficacy in this rare histotype of malignancy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hilal T. Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management. Ther Adv Med Oncol. 2017;9(3):189–99.

    Article  Google Scholar 

  2. Basu B, Sirohi B, Corrie P. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocr Relat Cancer. 2010;17(1):75–90.

    Article  Google Scholar 

  3. Scalettar BA, Jacobs C, Fulwiler A, et al. Hindered submicron mobility and long-term storage of presynaptic dense-core granules revealed by single-particle tracking. Dev Neurobiol. 2012;72(9):1181–95.

    Article  CAS  Google Scholar 

  4. Oronsky B, Ma PC, Morgensztern B, et al. Nothing but NET; a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19:991–1002.

    Article  CAS  Google Scholar 

  5. Anaizi A, Rizvi-Toner A, Valestin J, et al. Large cell neuroendocrine carcinoma of the lung presenting as pseudoachalasia: a case report. J Med Case Rep. 2015;9:56.

    Article  Google Scholar 

  6. Williams E, Sandler M. The classification of carcinoid tumours. Lancet. 1963;281(7275):238–9.

    Article  Google Scholar 

  7. Axiotis CA. The neuroendocrine lung. In: Volsi VL, Asa SL, editors. Endocrine pathology. New York: Churchill Livingstone; 2002. p. 261–96.

    Google Scholar 

  8. Travis WD. The concept of pulmonary neuroendocrine tumours. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.

    Google Scholar 

  9. Hendifar AE, Marchevsky AM, Tuli R. Neuroendocrine tumours of the lung; current challenges and advances in the diagnosis and management of well-differentiated disease. J Thorac Oncol. 2017;12(3):425–36.

    Article  Google Scholar 

  10. Limouris GS, Chatziioannou A, Kontogeorgakos D, et al. Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuro-endocrine liver metastases. Eur J Nucl Med Mol Imaging. 2008;35:1827–37.

    Article  CAS  Google Scholar 

  11. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumours. Clin Cancer Res. 2007;13:2986–299.

    Article  CAS  Google Scholar 

  12. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26:3403–10.

    Article  CAS  Google Scholar 

  13. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26:4311–8.

    Article  Google Scholar 

  14. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer. 2006;95:1148–54.

    Article  CAS  Google Scholar 

  15. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378:2005–12.

    Article  CAS  Google Scholar 

  16. Yao JC, Fazio N, Singh S, et al. RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968–77.

    Article  CAS  Google Scholar 

  17. Fazio N, Granberg D, Grossman A, et al. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. Chest. 2013;143:955–62.

    Article  CAS  Google Scholar 

  18. Papotti M, Groce S, Macri D, et al. Correlative immuno-histochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. Diagn Mol Pathol. 2000;9:47–57.

    Article  CAS  Google Scholar 

  19. Limouris GS, Karfis I, Paphiti MI, et al. The drawback to treat neuroendocrine bronchial tumors with high doses of radiolabelled somatostatin analogs. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 2):457. [abstr].

    Google Scholar 

  20. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1Tyr3octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12:941–5.

    Article  CAS  Google Scholar 

  21. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med. 2002;43(5):610–6.

    CAS  PubMed  Google Scholar 

  22. Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabelled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416–23.

    Article  CAS  Google Scholar 

  23. Filice A, Fraternali A, Frasoldati A, et al. Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experience. J Oncol. 2012;2012:320198. https://doi.org/10.1155/2012/320198.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0, Tyr3] octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617–24.

    Article  CAS  Google Scholar 

  25. Van Essen M, Krenning EP, Kooij PP, et al. Effects of therapy with peptide receptor radionuclide therapy with [177Lu-DOTA0, Tyr3] octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47:1599–606.

    PubMed  Google Scholar 

  26. Van Essen M, Krenning EP, Bakker WH, et al. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging. 2007;34(8):1219–27.

    Article  Google Scholar 

  27. Sabet A, Haug AR, Eiden C, et al. Efficacy of peptide receptor radio-nuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis. Am J Nucl Med Mol Imaging. 2017;7(2):74–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Garske-Román U, Sandström M, Fröss-Baron K, et al. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45:970–88.

    Article  Google Scholar 

  29. Mariniello A, Bodei L, Tinelli C, et al. Long-term results of PRRT in advanced bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging. 2016;43(3):441–52.

    Article  CAS  Google Scholar 

  30. Ianniello A, Sansovini M, Severi S, et al. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. Eur J Nucl Med Mol Imaging. 2016;43(6):1040–6.

    Article  CAS  Google Scholar 

  31. van der Zwan WA, Brabander T, Kam BLR, et al. Salvage peptide receptor radionuclide therapy with [177Lu-DOTA, Tyr3] octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2019;46(3):704–17.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece

    Georgios S. Limouris

  2. Nuclear Medicine Department, Army Share Fund Hospital of Athens, Athens, Greece

    Athanasios G. Zafeirakis

Authors
  1. Georgios S. Limouris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Athanasios G. Zafeirakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georgios S. Limouris .

Editor information

Editors and Affiliations

  1. Nuclear Medicine, Medical School National and Kapodistrian University of Athens, Athens, Greece

    Georgios S. Limouris

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Limouris, G.S., Zafeirakis, A.G. (2021). 111In-Octreotide Infusions for the Treatment of Bronchopulmonary Neuroendocrine Neoplasms. In: Limouris, G.S. (eds) Liver Intra-arterial PRRT with 111In-Octreotide. Springer, Cham. https://doi.org/10.1007/978-3-030-70773-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-70773-6_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-70772-9

  • Online ISBN: 978-3-030-70773-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation